Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiangjurupining Capsule in Hyperplasia of Breast
NCT04229706Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Xiangjurupining Capsule placebo in breast hyperplasia (3 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoints: The pain of breast at 3 months, The days of pain at 3 months and 3 more. Started Dec 2019; status: completed.
02
Drugs
Xiangjurupining Capsule placebo
03
Conditions
breast hyperplasia
Beyond the preview
Go deeper on NCT04229706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229706.